Condition
CDH17-positive Advanced Solid Tumors
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 1 (1)
Trial Status
Recruiting1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07529808Phase 1Not Yet Recruiting
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT06820424Early Phase 1RecruitingPrimary
Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors
Showing all 2 trials